{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:40:40Z","timestamp":1794433240284,"version":"4.9.1"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejmech.2024.116442","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T07:28:39Z","timestamp":1714030119000},"page":"116442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1448-431X","authenticated-orcid":false,"given":"Zirui","family":"L\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiandong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanhua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","article-title":"Infectious disease in an era of global change","volume":"20","author":"Baker","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116442_bib2","unstructured":"Organization W H. Disease Outbreak News (DONs) [EB\/OL]. [3]. https:\/\/www.who.int\/emergencies\/disease-outbreak-news."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020206","article-title":"COVID-19: characteristics and therapeutics","volume":"10","author":"Chilamakuri","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116442_bib5","series-title":"WHO Coronavirus (COVID-19) Dashboard[EB\/OL]","year":"2023"},{"issue":"6232","key":"10.1016\/j.ejmech.2024.116442_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1126\/science.aaa3778","article-title":"Infectious disease. Combating emerging viral threats","volume":"348","author":"Bekerman","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/med.21664","article-title":"Medicinal chemistry strategies toward host targeting antiviral agents","volume":"40","author":"Ji","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"6232","key":"10.1016\/j.ejmech.2024.116442_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1126\/science.aaa3778","article-title":"Infectious disease. Combating emerging viral threats","volume":"348","author":"Bekerman","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116442_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2018.04.016","article-title":"Novel activities of safe-in-human broad-spectrum antiviral agents","volume":"154","author":"Ianevski","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib10","series-title":"Molecular Cell Biology","year":"2000"},{"key":"10.1016\/j.ejmech.2024.116442_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.coviro.2019.01.004","article-title":"Virus recognition of glycan receptors","volume":"34","author":"Thompson","year":"2019","journal-title":"Curr. Opin. Virol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0306-3623(96)00563-0","article-title":"Sulfated polysaccharides extracted from sea algae as potential antiviral drugs","volume":"29","author":"Witvrouw","year":"1997","journal-title":"Gen. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib13","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/AAC.32.11.1742","article-title":"Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus","volume":"32","author":"Baba","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116442_bib14","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2174\/0929867043364504","article-title":"Sulfated seaweed polysaccharides as antiviral agents","volume":"11","author":"Damonte","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/glycob\/cwn092","article-title":"Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation","volume":"19","author":"Ghosh","year":"2009","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2005.08.006","article-title":"Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses","volume":"69","author":"Lee","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102038","article-title":"Efficacy and safety of a self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women (CATCH study): an exploratory phase IIB randomised, placebo-controlled trial","volume":"60","author":"Laurie","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib18","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/infdis\/jis273","article-title":"A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses","volume":"205","author":"Krepstakies","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib19","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.00471-10","article-title":"Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses","volume":"54","author":"Donalisio","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"28","key":"10.1016\/j.ejmech.2024.116442_bib20","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1002\/chem.201501030","article-title":"Antiviral activity of synthetic aminopyrrolic carbohydrate binding agents: targeting the glycans of viral gp120 to inhibit HIV entry","volume":"21","author":"Francesconi","year":"2015","journal-title":"Chemistry"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116442_bib21","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/acs.jmedchem.9b00142","article-title":"Anti-zika activity of a library of synthetic carbohydrate receptors","volume":"62","author":"Palanichamy","year":"2019","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.116442_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/acs.biochem.0c00732","article-title":"Flexible synthetic carbohydrate receptors as inhibitors of viral attachment","volume":"60","author":"Bravo","year":"2021","journal-title":"Biochemistry"},{"issue":"Suppl 6","key":"10.1016\/j.ejmech.2024.116442_bib23","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1093\/infdis\/jiac426","article-title":"The picornaviridae family: knowledge gaps, animal models, countermeasures, and prototype pathogens","volume":"228","author":"Andino","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116442_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ejmech.2019.06.008","article-title":"Back to the future: advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses","volume":"178","author":"Egorova","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0166-3542(93)90064-P","article-title":"SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating","volume":"21","author":"Rozhon","year":"1993","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib26","first-page":"335","article-title":"Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model","volume":"215","author":"Collett","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib27","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.48.5.1766-1772.2004","article-title":"In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity","volume":"48","author":"Barnard","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib28","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1128\/AAC.03328-14","article-title":"The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication","volume":"58","author":"Tijsma","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2024.116442_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12985-015-0330-4","article-title":"In vitro characterisation of a pleconaril\/pirodavir-like compound with potent activity against rhinoviruses","volume":"12","author":"Lacroix","year":"2015","journal-title":"Virol. J."},{"issue":"4770","key":"10.1016\/j.ejmech.2024.116442_bib30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1126\/science.3018924","article-title":"The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating","volume":"233","author":"Smith","year":"1986","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib31","first-page":"335","article-title":"Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model","volume":"215","author":"Collett","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000281","article-title":"A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses","volume":"17","author":"Abdelnabi","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2024.116442_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1146\/annurev-biochem-060208-104626","article-title":"Virus entry by endocytosis","volume":"79","author":"Mercer","year":"2010","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MJT.0b013e3181754134","article-title":"HPV16 and BPV1 infection can be blocked by the dynamin inhibitor dynasore","volume":"15","author":"Abban","year":"2008","journal-title":"Am. J. Therapeut."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116442_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/v8120322","article-title":"Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models","volume":"8","author":"Delvecchio","year":"2016","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116442_bib36","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.antiviral.2013.08.008","article-title":"Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking","volume":"100","author":"Blaising","year":"2013","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"Andrews","year":"1982","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116442_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/v11020176","article-title":"Identification of broad-spectrum antiviral compounds by targeting viral entry","volume":"11","author":"Mazzon","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2024.116442_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114295","article-title":"Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2","volume":"235","author":"Juang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1586\/eri.12.104","article-title":"Development of novel entry inhibitors targeting emerging viruses","volume":"10","author":"Zhou","year":"2012","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejmech.2024.116442_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib45","first-page":"42","article-title":"[Study of the effect of antiviral drugs on the reproduction of the respiratory syncytial virus by enzyme immunoassay]","volume":"47","author":"Leneva","year":"2002","journal-title":"Vopr. Virusol."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116442_bib46","first-page":"84","article-title":"[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]","volume":"77","author":"Leneva","year":"2005","journal-title":"Ter. Arkh."},{"issue":"25","key":"10.1016\/j.ejmech.2024.116442_bib47","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.12998\/wjcc.v9.i25.7350","article-title":"Efficacy of arbidol in COVID-19 patients: a retrospective study","volume":"9","author":"Wei","year":"2021","journal-title":"World. J. Clin. Cases."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib48","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116442_bib49","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1002\/iid3.984","article-title":"Arbidol: the current demand, strategies, and antiviral mechanisms","volume":"11","author":"Kang","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib50","first-page":"24","article-title":"[Monitoring of the sensitivity of epidemic influenza virus strains isolated in Russia to etiotropic chemical agents]","volume":"54","author":"Burtseva","year":"2009","journal-title":"Vopr. Virusol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tim.2009.08.002","article-title":"Dealing with low pH: entry and exit of alphaviruses and flaviviruses","volume":"17","author":"Sanchez-San","year":"2009","journal-title":"Trends Microbiol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cbf.3182","article-title":"Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity","volume":"34","author":"Akpovwa","year":"2016","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejmech.2024.116442_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104619","article-title":"Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses","volume":"107","author":"Lu","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116442_bib55","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses","volume":"107","author":"Wolf","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"40","key":"10.1016\/j.ejmech.2024.116442_bib56","doi-asserted-by":"crossref","first-page":"17024","DOI":"10.1021\/jacs.0c06400","article-title":"Supramolecular mechanism of viral envelope disruption by molecular tweezers","volume":"142","author":"Weil","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116442_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/2040206620976786","article-title":"Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections","volume":"28","author":"Huchting","year":"2020","journal-title":"Antivir. Chem. Chemother."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116442_bib58","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1073\/pnas.1101143108","article-title":"Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis","volume":"108","author":"Hoffmann","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6\u20137","key":"10.1016\/j.ejmech.2024.116442_bib59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/15257770701490506","article-title":"IMPDH as a biological probe for RNA antiviral drug discovery: synthesis, enzymology, molecular docking, and antiviral activity of new ribonucleosides with surrogate bases","volume":"26","author":"Nair","year":"2007","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"issue":"4050","key":"10.1016\/j.ejmech.2024.116442_bib60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib62","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","article-title":"Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent","volume":"70","author":"Streeter","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.14218\/JCTH.2018.00007","article-title":"Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era","volume":"6","author":"Mathur","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00152711","article-title":"Ribavirin: a clinical overview","volume":"2","author":"Fernandez","year":"1986","journal-title":"Eur. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib65","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/hep.23204","article-title":"Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders","volume":"50","author":"Rustgi","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1328-8067.2002.01536.x","article-title":"Mizoribine: mode of action and effects in clinical use","volume":"44","author":"Yokota","year":"2002","journal-title":"Pediatr. Int."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2024.116442_bib67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2005.01.003","article-title":"Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus","volume":"66","author":"Saijo","year":"2005","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib68","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/AAC.24.3.353","article-title":"Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent","volume":"24","author":"Kirsi","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib69","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/0006-2952(82)90436-1","article-title":"The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties","volume":"31","author":"Cooney","year":"1982","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib70","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1172\/JCI111750","article-title":"Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic \"C\" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy","volume":"75","author":"Berger","year":"1985","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib71","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.26.4.476","article-title":"Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses","volume":"26","author":"Huggins","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib72","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/095632020701800501","article-title":"Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery","volume":"18","author":"Nair","year":"2007","journal-title":"Antivir. Chem. Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116442_bib73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/092986730607220401123549","article-title":"Mizoribine and mycophenolate mofetil","volume":"6","author":"Ishikawa","year":"1999","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116442_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24091723","article-title":"In vitro and in vivo antiviral activity of mizoribine against foot-and-mouth disease virus","volume":"24","author":"Li","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116442_bib75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2018.01.002","article-title":"The role of adjuvant immunomodulatory agents for treatment of severe influenza","volume":"150","author":"Hui","year":"2018","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib76","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/095632020101200602","article-title":"Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro","volume":"12","author":"Smee","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2024.116442_bib77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2013.07.053","article-title":"Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines","volume":"69","author":"Zhong","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib78","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0092-8674(00)81275-1","article-title":"Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid","volume":"85","author":"Sintchak","year":"1996","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib79","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/molecules19010925","article-title":"Synthesis and broad-spectrum antiviral activity of some novel benzo-heterocyclic amine compounds","volume":"19","author":"Zhang","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116442_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2017.11.004","article-title":"Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens","volume":"149","author":"Tong","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111681","article-title":"Dihydroorotate dehydrogenase inhibitors in anti-infective drug research","volume":"183","author":"Boschi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib82","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/15257770.2018.1460479","article-title":"Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines","volume":"37","author":"Peters","year":"2018","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-18-0863","article-title":"Targeting of hematologic malignancies with PTC299, A novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties","volume":"18","author":"Cao","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116442_bib84","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2174\/138955711797247707","article-title":"Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors","volume":"11","author":"Vyas","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/v14050928","article-title":"A broad antiviral strategy: inhibitors of human DHODH pave the way for host-targeting antivirals against emerging and Re-emerging viruses","volume":"14","author":"Zheng","year":"2022","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116442_bib86","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0006-2952(98)00145-2","article-title":"Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives","volume":"56","author":"Knecht","year":"1998","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijantimicag.2011.07.002","article-title":"Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture","volume":"38","author":"Schnellrath","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116442_bib88","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1128\/AAC.00561-10","article-title":"Characterization of dengue virus resistance to brequinar in cell culture","volume":"54","author":"Qing","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116442_bib89","article-title":"Identification of inhibitors of ZIKV replication","volume":"12","author":"Morales","year":"2020","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/v11100964","article-title":"Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine","volume":"11","author":"Andersen","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2024.116442_bib91","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2018.08.012","article-title":"Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses","volume":"158","author":"Luthra","year":"2018","journal-title":"Antivir. Res."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib92","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"issue":"7904","key":"10.1016\/j.ejmech.2024.116442_bib93","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"Schultz","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116442_bib94","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/bi001810q","article-title":"Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase","volume":"40","author":"McLean","year":"2001","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib95","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1165\/rcmb.2007-0142OC","article-title":"Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection","volume":"37","author":"Davis","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"27","key":"10.1016\/j.ejmech.2024.116442_bib96","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.18632\/oncotarget.17863","article-title":"Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication","volume":"8","author":"Bilger","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116442_bib97","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.1096\/fj.201902793RR","article-title":"A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases","volume":"34","author":"Wang","year":"2020","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib98","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/JVI.01737-09","article-title":"Leflunomide inhibition of BK virus replication in renal tubular epithelial cells","volume":"84","author":"Bernhoff","year":"2010","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1399-3062.2011.00682.x","article-title":"Leflunomide for cytomegalovirus: bench to bedside","volume":"14","author":"Chacko","year":"2012","journal-title":"Transpl. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12250-020-00258-7","article-title":"A small-scale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial","volume":"35","author":"Hu","year":"2020","journal-title":"Virol. Sin."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib101","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/jm501127s","article-title":"Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase","volume":"58","author":"Zhu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116442_bib102","article-title":"Rational design of benzylidenehydrazinyl-substituted thiazole derivatives as potent inhibitors of human dihydroorotate dehydrogenase with in vivo anti-arthritic activity","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116442_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198246","article-title":"The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines","volume":"292","author":"Luban","year":"2021","journal-title":"Virus Res."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib104","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1099\/jgv.0.000758","article-title":"Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response","volume":"98","author":"Cheung","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116442_bib105","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1073\/pnas.1101143108","article-title":"Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis","volume":"108","author":"Hoffmann","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02329-18","article-title":"Origins and evolution of the global RNA virome","volume":"9","author":"Wolf","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2024.116442_bib107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","article-title":"RNA virus mutations and fitness for survival","volume":"51","author":"Domingo","year":"1997","journal-title":"Annu. Rev. Microbiol."},{"issue":"396","key":"10.1016\/j.ejmech.2024.116442_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"396","key":"10.1016\/j.ejmech.2024.116442_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib110","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116442_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00254-22","article-title":"Population pharmacokinetics of remdesivir and GS-441524 in hospitalized COVID-19 patients","volume":"66","author":"Leegwater","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib113","doi-asserted-by":"crossref","DOI":"10.15190\/d.2022.10","article-title":"Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children","volume":"10","author":"Chera","year":"2022","journal-title":"Discoveries"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib114","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00001432-200112000-00015","article-title":"The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase","volume":"14","author":"Cameron","year":"2001","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib115","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jiy398","article-title":"A single nucleoside viral polymerase inhibitor against norovirus, rotavirus, and sapovirus-induced diarrhea","volume":"218","author":"Van Dycke","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib116","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116442_bib118","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116442_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2019.04.002","article-title":"Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir)","volume":"167","author":"Huchting","year":"2019","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1582-4934.2008.00273.x","article-title":"Heat shock proteins: essential proteins for apoptosis regulation","volume":"12","author":"Lanneau","year":"2008","journal-title":"J. Cell Mol. Med."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116442_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179366","article-title":"Role of heat shock proteins (HSP70 and HSP90) in viral infection","volume":"22","author":"Lubkowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib122","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cell.2015.10.046","article-title":"Defining Hsp70 subnetworks in dengue virus replication reveals key vulnerability in flavivirus infection","volume":"163","author":"Taguwa","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116442_bib123","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2016.01.012","article-title":"Allosteric heat shock protein 70 inhibitors block hepatitis C virus assembly","volume":"47","author":"Khachatoorian","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/22221751.2018.1557988","article-title":"Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and egress from host cells","volume":"8","author":"Pujhari","year":"2019","journal-title":"Emerg. Microb. Infect."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116442_bib125","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.bmcl.2017.03.025","article-title":"Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton","volume":"27","author":"Li","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116442_bib126","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.bmcl.2013.02.089","article-title":"Evaluation of anti-HCV activity and SAR study of (+)-lycoricidine through targeting of host heat-stress cognate 70 (Hsc70)","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)80203-2","article-title":"Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent","volume":"89","author":"Stebbins","year":"1997","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056762","article-title":"Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus","volume":"8","author":"Geller","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116442_bib129","first-page":"397","article-title":"Hsp90 inhibitor AT-533 blocks HSV-1 nuclear egress and assembly","volume":"164","author":"Li","year":"2018","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2024.116442_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104590","article-title":"Small molecule grp94 inhibitors block dengue and Zika virus replication","volume":"171","author":"Rothan","year":"2019","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib131","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0092-8674(95)90395-X","article-title":"Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum","volume":"81","author":"Hebert","year":"1995","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib132","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1042\/BST20160182","article-title":"Iminosugar antivirals: the therapeutic sweet spot","volume":"45","author":"Alonzi","year":"2017","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib133","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.antiviral.2013.06.011","article-title":"Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions","volume":"99","author":"Chang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12777","article-title":"Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities","volume":"7","author":"Ahmed-Belkacem","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116442_bib135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-micro-092611-150203","article-title":"A virological view of innate immune recognition","volume":"66","author":"Iwasaki","year":"2012","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116442_bib136","series-title":"Alinia\u00ae (Nitazoxanide) Prescribing Information[s]","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116442_bib137","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib138","doi-asserted-by":"crossref","DOI":"10.1038\/srep27148","article-title":"Thiazolides elicit anti-viral innate immunity and reduce HIV replication","volume":"6","author":"Trabattoni","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116442_bib139","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116442_bib140","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus","volume":"19","author":"Jasenosky","year":"2019","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib141","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1002\/jmv.27891","article-title":"Identification of clinical candidates against West Nile virus by activity screening in vitro and effect evaluation in vivo","volume":"94","author":"Tang","year":"2022","journal-title":"J. Med. Virol."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib142","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nbt.2391","article-title":"Systematic identification of synergistic drug pairs targeting HIV","volume":"30","author":"Tan","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2024.116442_bib143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-422X-11-10","article-title":"Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model","volume":"11","author":"Shi","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.ejmech.2024.116442_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.010","article-title":"A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs","volume":"114","author":"Cao","year":"2015","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116442_bib145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116442_bib146","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116442_bib147","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation","volume":"137","author":"Elazar","year":"2009","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib148","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00707-18","article-title":"Nitazoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response","volume":"62","author":"Dang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116442_bib149","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1007\/s11033-022-07822-2","article-title":"Nitazoxanide and COVID-19: a review","volume":"49","author":"Al-Kuraishy","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116442_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/v14102200","article-title":"Revisiting viral RNA-dependent RNA polymerases: insights from recent structural studies","volume":"14","author":"Ramaswamy","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2024.116442_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131756","article-title":"RdRp (RNA-dependent RNA polymerase): a key target providing anti-virals for the management of various viral diseases","volume":"1250","author":"Pathania","year":"2022","journal-title":"J. Mol. Struct."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:37:24Z","timestamp":1717234644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424003222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":151,"alternative-id":["S0223523424003222"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116442","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116442"}}